Commonwealth Bank iconography atop a modern building at dusk. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Shares in ASX-listed lenders’ insurer Helia (ASX:HLI) – formerly Genworth – fell -17% in afternoon trades on Wednesday as Commonwealth Bank (ASX:CBA) gave notice to the company it wants to alter an existing contract with Helia.

Currently, Helia provides insurance for Commonwealth’s mortgage lending division; a contract which underpins much of the fundamental value proposition for Helia’s shareholders.

The wording of Helia’s announcement on Wednesday was ultimately unclear on what exactly CBA wants to do with the contract – though the language used hinted at a possible extension of coverage to the entire CBA group, which includes BankWest.

However – and this is likely what has spooked the market – that contract, inked in January 2022, was meant to last until 2025.

Clearly, despite some possibly positive language in Helia’s announcement on Wednesday, the market isn’t so sure.

That the company is back to negotiations well short of the contract’s original expiry date has been enough to amplify worries in an ASX not particularly defined by a risk-off atmosphere of late.

What exactly transpires for Helia remains to be seen. But as of mid-afternoon, it’s been enough to put Helia at the top of today’s biggest single-company declines on the ASX.

HLI last traded at $3.50.

HLI by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: Another reversal as just-green Oz markets ignore US dive | Jan 3, 2024

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next